CSL Behring Nanofiltered Immune Globulin Intravenous ( Human ) ,
نویسنده
چکیده
DESCRIPTION Carimune® NF, Nanofiltered, Immune Globulin Intravenous (Human), is a sterile, highly purified polyvalent antibody product containing in concentrated form all the IgG antibodies which regularly occur in the donor population.1 This immunoglobulin preparation is produced by cold alcohol fractionation from the plasma of US donors. Part of the fractionation may be performed by another US-licensed manufacturer. Carimune® NF is made suitable for intravenous use by treatment at acid pH in the presence of trace amounts of pepsin.2,3 The manufacturing process by which Carimune® NF is prepared from plasma consists of fractionation and purification steps that comprise filtrations in the presence of filter aids. Four of these steps were validated for virus elimination of both enveloped and non-enveloped viruses. Additionally, the manufacturing process was investigated for its capacity to decrease the infectivity of an experimental agent of transmissible spongiform encephalopathy (TSE), considered as a model for the vCJD and CJD agents.4 To complement the existing virus elimination / inactivation mechanism in the Carimune® NF manufacturing process, nanofiltration (removing viruses via size-exclusion) was introduced as an additional virus removal step into the manufacturing process.5,6 Nanofiltration is performed prior to the viral inactivation step (pH 4 in presence of pepsin) in order to reduce the potential viral load before inactivation is performed. Treatment with pepsin at pH 4 rapidly inactivates enveloped viruses.7 The Carimune® NF manufacturing process provides a significant virus reduction capacity as shown in in vitro studies. The results, summarized in Table 1, demonstrate virus clearance during Carimune® NF manufacturing using model viruses for lipid enveloped and nonenveloped viruses. Table 1: Virus Elimination and Inactivation
منابع مشابه
Therapy for Alpha-1 Antitrypsin Deficiency: the Evidence for Efficacy
Disclosure: David Parr has received honoraria for advising CSL Behring and Grifols (formerly Talecris), in addition to sponsorship from AstraZeneca and Boehringer Ingelheim. Emer Reeves and Niels Seersholm have no competing interests to disclose; however, both have received honoraria for this educational activity funded by CSL Behring. Kenneth R. Chapman has received compensation for consulting...
متن کاملUse of a C1 Inhibitor Concentrate in Adults ≥65 Years of Age with Hereditary Angioedema: Findings from the International Berinert® (C1-INH) Registry
BACKGROUND Treatment of hereditary angioedema (HAE) in 'older adults' (those aged ≥65 years) has not been well studied. The international Berinert Patient Registry collected data on the use of intravenous plasma-derived, pasteurized, nanofiltered C1-inhibitor concentrate (pnfC1-INH; Berinert®/CSL Behring) in patients of any age, including many older adults. METHODS This observational registry...
متن کاملDefining von Willebrand disease.
for repeat testing. The authors’ conclusion that it should be considered for screening patients requires further consideration and study but conceivably, this assay should improve the future of VWD diagnosis. Conflict-of-interest disclosure: P.D.J. has received research funding from Bayer, CSL Behring, and Octapharma; and honoraria for educational talks from Baxalta, CSL Behring, and Octapharma. n
متن کاملSafety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy.
BACKGROUND Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a common inflammatory neuropathy that can be progressive, stepwise progressive, or relapsing and remitting. OBJECTIVES To further evaluate the long-term safety and tolerability of immune globulin intravenous, 10% caprylate-chromatography purified immune globulin intravenous in CIDP. DESIGN Randomized multicenter ...
متن کاملControlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin.
We performed a randomized, controlled trial of intravenous immune globulin (respiratory syncytial virus [RSV] neutralizing [Nt] antibody titer of 1:950 in 5% solution) to evaluate protection against RSV-induced disease over two respiratory virus seasons. Forty-nine children (mean age at enrollment, 4.5 months) with severe congenital heart disease or bronchopulmonary dysplasia were randomized as...
متن کامل